It was the biggest loser on the Bloomberg Massachusetts Index: Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), down more than 12 percent. The Cambridge company is developing a new class of medicines based on RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising approach to silence disease-causing genes, according to its website. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock performance was -12.11% in last session and finished the day at $57.92. Traded volume was 1.12million shares in the last session and the average volume of the stock remained 808.10K shares. The beta of the stock remained 1.29. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insider ownership is 0.20%.
Six insiders sold Sangamo BioSciences Inc. (NASDAQ:SGMO) stock within one month. Sangamo BioSciences Inc. (NASDAQ:SGMO) focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Sangamo Biosciences, Inc. (NASDAQ:SGMO) dropped -8.34 percent to $14.95 Thursday on volume of 1.23million shares. The intra-day range of the stock was $14.65 to $16.25. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has a market capitalization of $996.99million.
Dyax Corp. (NASDAQ:DYAX) the biopharmaceutical service provider which has finally received positive news for its plasma inhibitor called KALBITOR. Dyax Corp. (NASDAQ:DYAX) has reported that this drug is the only approved therapy which will not purify human plasma, when it is used to treat patient populations. KALBITOR is the only product Dyax Corp (NASDAQ:DYAX) markets. Dyax Corp. (NASDAQ:DYAX)’s stock on Apr 10, 2014 reported a decrease of -9.57% to the closing price of $7.94. Its fifty two weeks range is $2.26 -$10.99. The total market capitalization recorded $1.08billion. The overall volume in the last trading session was 1.53million shares. In its share capital, DYAX has 134.54million outstanding shares.
On March 27, 2014, the board of directors of Synthetic Biologics, Inc. (NYSEMKT:SYN) determined to hold its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2014. The record date, time and location of the Annual Meeting will be as set forth in the Company’s proxy statement for the Annual Meeting. On Thursday, shares of Synthetic Biologics Inc (NYSEMKT:SYN) advanced 5.98% to close the day at $2.48. Company monthly performance is recorded as -14.48%. Synthetic Biologics Inc (NYSEMKT:SYN) quarterly revenue growth is 34.05%.